Keiichi Jingu

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Rei Umezawa · 5 shared papers, 2012–2023 · strength 0.57
   • Paper Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy … DOI 10.1016/j.pan.2023.07.002↗
   • Paper Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated ra… DOI 10.1093/jrr/rrac049↗
   • Paper A Pilot Study of Synchronization of Respiration-Induced Motions in the Duodenum and Stomach for the Primary Tumor in Ra… DOI 10.1016/j.adro.2021.100730↗
2. Kei Nakagawa · 2 shared papers, 2022–2023 · strength 0.32
   • Paper Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy … DOI 10.1016/j.pan.2023.07.002↗
   • Paper Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated ra… DOI 10.1093/jrr/rrac049↗
3. Masamichi Mizuma · 2 shared papers, 2022–2023 · strength 0.32
   • Paper Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy … DOI 10.1016/j.pan.2023.07.002↗
   • Paper Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated ra… DOI 10.1093/jrr/rrac049↗
4. Michiaki Unno · 2 shared papers, 2022–2023 · strength 0.32
   • Paper Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy … DOI 10.1016/j.pan.2023.07.002↗
   • Paper Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated ra… DOI 10.1093/jrr/rrac049↗
5. Jun Itami · 2 shared papers, 2020–2021 · strength 0.22
   • Paper A Pilot Study of Synchronization of Respiration-Induced Motions in the Duodenum and Stomach for the Primary Tumor in Ra… DOI 10.1016/j.adro.2021.100730↗
   • Paper How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic… DOI 10.1016/j.adro.2019.08.014↗
6. Ikuro Sato · 1 shared paper, 2022 · strength 0.12
   • Paper PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. DOI 10.1111/cas.15315↗
7. Hiroyuki Kato · 1 shared paper, 2022 · strength 0.12
   • Paper PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. DOI 10.1111/cas.15315↗
8. Keiichi Tamai · 1 shared paper, 2022 · strength 0.12
   • Paper PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. DOI 10.1111/cas.15315↗
9. Katsuya Fukui · 1 shared paper, 2022 · strength 0.12
   • Paper PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. DOI 10.1111/cas.15315↗
10. Hiroshi Shima · 1 shared paper, 2022 · strength 0.12
    • Paper PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. DOI 10.1111/cas.15315↗
11. Kennichi Satoh · 1 shared paper, 2022 · strength 0.12
    • Paper PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. DOI 10.1111/cas.15315↗
12. Toru Furukawa · 1 shared paper, 2022 · strength 0.12
    • Paper PP6 deficiency in mice with KRAS mutation and Trp53 loss promotes early death by PDAC with cachexia-like features. DOI 10.1111/cas.15315↗
13. Shogo Yamada · 1 shared paper, 2012 · strength 0.03
    • Paper Intraoperative radiotherapy for pancreatic cancer: 30-year experience in a single institution in Japan. DOI 10.1016/j.ijrobp.2012.01.024↗
14. Yoshihiro Ogawa · 1 shared paper, 2012 · strength 0.03
    • Paper Intraoperative radiotherapy for pancreatic cancer: 30-year experience in a single institution in Japan. DOI 10.1016/j.ijrobp.2012.01.024↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.